Top
Topic: Targeted cancer therapy

A special issue of Cancer Drug Resistance.

ISSN 2578-532X (Online)

Submission deadline: 3 Sep 2018

Guest Editor(s)

  • Dr. Elisa Giovannetti, MD, PhD
    Lab Medical Oncology, VU University Medical Center (VUmc), Cancer Center Amsterdam, The Netherlands.
    Cancer Pharmacology Lab, AIRC Start-Up Unit, University of Pisa, Italy.

    Website | E-mail

  • Dr. Jose Antonio Rodriguez, PhD
    Department of Genetics, Physical Anthropology and Animal Physiology (School of Medicine and Nursing) of the University of the Basque Country (UPV/EHU), Basque Country, Spain.

    Website | E-mail

Special Issue Introduction

Targeted therapies in cancer aim to specifically block the activity of crucial proteins or signaling pathways necessary for the growth and/or survival of tumor cells. A major breakthrough in targeted cancer therapy was the introduction nearly two decades ago of imatinib, an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myeloid leukemia. Over the last years, significant advances in our understanding of tumor biology have facilitated the development of many drugs targeting not only kinases, but also other protein families and cellular processes. Several of these agents are currently employed or being implemented for the treatment of different hematologic and solid malignancies, such as lung cancer.
The special issue on “Targeted cancer therapy” will include Reviews and Commentaries updating the clinical use of targeted agents in the treatment of different tumor types, and the mechanisms that underlie the action of drugs directed to different types of targets. The special issue will also include Research articles presenting novel outstanding data on all aspects of targeted cancer therapy. All submissions will undergo rigorous peer revision and will be published free of charge upon acceptance.

Keywords

Biomarkers, personalized medicine, new approaches to cancer treatment, molecularly targeted drugs, mechanisms of targeted drugs, resistance to targeted therapies, novel targets

Submission Deadline

3 Sep 2018

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://cdrjournal.com/pages/view/author_instructions
For Online Submission, please login at http://www.oaemesas.com/cdr
Submission Deadline: 3 Sep 2018
Contacts: Elaine Gao, Managing Editor, editorial@cdrjournal.com

Published Articles